On December 16, 2024, CS MEDICA communicated to Spotlight Stock Market that the outstanding payments would be settled within the week. The payments were completed on December 19, 2024, just one day after the stated deadline of December 18. In addition, CS MEDICA had proposed paying the Spotlight fee a year in advance to demonstrate the company’s improved financial stability. Despite these proactive efforts, Spotlight Stock Market released the delisting notification and has decided to proceed with delisting.

We are deeply surprised and disappointed by this decision, particularly given the strong relationship and support CS MEDICA has enjoyed with Spotlight Stock Market over the years. The timing of this announcement on the day immediately following the payment deadline has added unnecessary complexity and challenges for our company and our shareholders. We still hope to solve the situation with Spotlight.

CS MEDICA has always prioritized transparency, and we have openly communicated with our investors and stakeholders about the financial challenges we have faced in the recent year. This includes acknowledging the need for a cash injection to strengthen our financial position and our strategic goal of pursuing an IPO in Germany through our subsidiary. Overcoming these challenges has been a key focus for the company, and our founders have demonstrated their commitment by converting debt into shares, ensuring stability while fostering growth in a demanding market environment. This action underscores our dedication to mitigating risks and protecting shareholder interests.

We want to assure our shareholders and stakeholders that this development does not impact our daily operations, strategic growth initiatives, or the intrinsic value of the company. CS MEDICA is actively exploring alternative listing options to ensure continuity and safeguard the interests of our shareholders. Updates on our progress and next steps will be communicated promptly through official press releases.

We sincerely apologize for any concerns this situation may have caused and appreciate the trust and support of our investors and partners. CS MEDICA remains focused on delivering innovative solutions, driving business growth, and protecting the interests of all stakeholders.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
 

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
 

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.